Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund cut its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 95,180 shares of the medical equipment provider’s stock after selling 10,329 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Zimmer Biomet were worth $8,606,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ZBH. DV Equities LLC acquired a new stake in Zimmer Biomet during the fourth quarter worth about $25,000. Monetary Solutions Ltd purchased a new position in Zimmer Biomet during the fourth quarter valued at $30,000. Gen Wealth Partners Inc purchased a new position in Zimmer Biomet during the fourth quarter valued at $31,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Zimmer Biomet during the fourth quarter worth about $32,000. Finally, Grove Bank & Trust increased its stake in shares of Zimmer Biomet by 431.6% during the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 328 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

ZBH stock opened at $93.57 on Friday. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The stock has a market cap of $18.10 billion, a price-to-earnings ratio of 24.30, a price-to-earnings-growth ratio of 2.65 and a beta of 0.46. The business has a fifty day moving average of $86.99 and a two-hundred day moving average of $89.82.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating the consensus estimate of $1.86 by $0.23. The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ZBH shares. Citizens Jmp decreased their price target on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research note on Wednesday, April 29th. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Monday, July 6th. Leerink Partners assumed coverage on Zimmer Biomet in a research note on Monday, April 13th. They issued a “hold” rating and a $101.00 price target on the stock. Truist Financial reiterated a “hold” rating and set a $92.00 price target (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Finally, Citigroup decreased their price objective on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $100.70.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.28% of the stock is currently owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.